Table 5. Systemic Treatment Summary in Patients with Behçet Retinal Vasculitis.
| Treatment | Total | Peripheral vasculitis (n=23) | Posterior pole-involved vasculitis (n=63) | p value* |
|---|---|---|---|---|
| Topical steroids (%) | 60 (69.8) | 18 (78.3) | 42 (66.7) | 0.43 |
| Systemic corticosteroids (%) | 77 (87.5) | 19 (82.6) | 56 (88.9) | 0.48 |
| Immunosuppressive agents (%) | ||||
| Azathioprine | 54 (61.4) | 8 (34.8) | 44 (84.6) | 0.006 |
| Cyclosporin A | 41 (46.6) | 3 (13.0) | 37 (58.7) | <0.0001 |
| Colchicine | 37 (42.0) | 14 (60.9) | 22 (34.9) | 0.047 |
| Methotrexate | 24 (27.3) | 1 (4.3) | 22 (34.9) | 0.005 |
| Posterior subtenon triamcinolone injections (%) | 26 (29.5) | 3 (13.0) | 20 (31.7) | 0.10 |
| Intravitreal injections (%) | ||||
| Triamcinolone | 14 (15.9) | 2 (8.7) | 11 (17.5) | 0.50 |
| Bevacizumab | 12 (13.6) | 0 | 11 (17.5) | 0.032 |
| Methotrexate | 6 (6.8) | 1 (4.3) | 5 (7.9) | 0.99 |
| Immunomodulating agents (%) | ||||
| Infliximab | 2 (2.3) | 0 | 2 (3.2) | 0.99 |
| Interferon | 8 (9.1) | 0 | 7 (11.1) | 0.18 |
| Cyclophosphamide (%) | 5 (5.7) | 0 | 5 (7.9) | 0.32 |
| Intravenous steroid pulses (%) | 2 (2.3) | 0 | 2 (3.2) | 0.99 |
*Chi-square test (or Fisher's exact test).